PMID- 27814273
OWN - NLM
STAT- MEDLINE
DCOM- 20170313
LR  - 20170313
IS  - 1875-8592 (Electronic)
IS  - 1574-0153 (Linking)
VI  - 18
IP  - 1
DP  - 2017
TI  - Overexpressions of miR-212 are associated with poor prognosis of patients with 
      pancreatic ductal adenocarcinoma.
PG  - 35-39
LID - 10.3233/CBM-160671 [doi]
AB  - BACKGROUND: The miR-212 was among the top differentially expressed miRNAs in 
      pancreatic ductal adenocarcinoma (PDAC). OBJECTIVE: The aim of this study was to 
      investigate the expression of miR-212 in PDAC and evaluate its correlation with 
      major clinicopathologic features and patients' survival. METHODS: Fluorescence in 
      situ hybridization (FISH) was adopted to examine miRNA expression in 45 
      pancreatic cancer and 20 normal pancreatic tissues. The relationship of miR-212 
      expression with clinicopathologic parameters and clinical outcome was evaluated. 
      RESULTS: miR-212 was confirmed to have significantly higher expression in PDAC 
      compared with normal pancreatic tissues (51.1% vs 10%, p< 0.01). High expression 
      of miR-212 was significantly associated with tumor size (p = 0.048) and tumor 
      stage (p = 0.023). Moreover, in univariant analysis, patients with high 
      expression of miR-212 demonstrate significantly poorer overall survival (p= 
      0.02). CONCLUSIONS: High expression of miR-212 in PDAC is associated with shorter 
      overall survival. It may be not only a potential prognostic marker, but also a 
      possible therapeutic target in PDAC.
FAU - Wu, Zhengrong
AU  - Wu Z
FAU - Zhou, Liangjing
AU  - Zhou L
FAU - Ding, Guoping
AU  - Ding G
FAU - Cao, Liping
AU  - Cao L
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Cancer Biomark
JT  - Cancer biomarkers : section A of Disease markers
JID - 101256509
RN  - 0 (MIRN212 microRNA, human)
RN  - 0 (MicroRNAs)
SB  - IM
MH  - Carcinoma, Pancreatic Ductal/*genetics/metabolism/mortality/pathology
MH  - Female
MH  - Humans
MH  - Male
MH  - MicroRNAs/*biosynthesis/genetics
MH  - Middle Aged
MH  - Pancreatic Neoplasms/*genetics/metabolism/mortality/pathology
MH  - Prognosis
MH  - Survival Analysis
OTO - NOTNLM
OT  - Pancreatic neoplasms
OT  - Prognosis
OT  - microRNA-212
EDAT- 2016/11/05 06:00
MHDA- 2017/03/14 06:00
CRDT- 2016/11/05 06:00
PHST- 2016/11/05 06:00 [pubmed]
PHST- 2017/03/14 06:00 [medline]
PHST- 2016/11/05 06:00 [entrez]
AID - CBM671 [pii]
AID - 10.3233/CBM-160671 [doi]
PST - ppublish
SO  - Cancer Biomark. 2017;18(1):35-39. doi: 10.3233/CBM-160671.